Adma Biologics (ADMA) Interest & Investment Income (2011 - 2026)
Adma Biologics' (ADMA) quarterly Interest & Investment Income came in at $487000.0 in Q4 2025, down 18.56% YoY from $598000.0 in Q4 2024, and up 29.52% on a QoQ basis from $376000.0 in Q3 2025.
Powered by 
Analysis
Adma Biologics (ADMA) Interest & Investment Income (2011 - 2026) Analysis & Trends
Adma Biologics (ADMA) has 13 years of Interest & Investment Income data on file, last reported at $487000.0 in Q4 2025.
- Quarterly Interest & Investment Income fell 18.56% year-over-year to $487000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.9 million (down 10.78% YoY) and the FY2025 annual result came in at $1.9 million, down 10.78% from the prior year.
- Interest & Investment Income climbed to $487000.0 in Q4 2025, from $376000.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $666000.0 in Q3 2024 to a low of $2269.0 in Q2 2022.
- A 5-year average of $283150.0 and a median of $380000.0 in 2024 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2021 — Interest & Investment Income slumped 91.11% — and 2023, when it soared 25116.32%.
- Tracing ADMA's Interest & Investment Income over 5 years: stood at $2759.0 in 2021, then retreated by 12.03% to $2427.0 in 2022, then soared by 25116.32% to $612000.0 in 2023, then fell by 2.29% to $598000.0 in 2024, then dropped by 18.56% to $487000.0 in 2025.
- The last three Interest & Investment Income figures came in at $487000.0 (Q4 2025), $376000.0 (Q3 2025), and $400000.0 (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Adma Biologics | 2.18 Bn | 2.04 Bn | 86.28 Mn | 1.24 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.24 Mn |
| Mar 31, 2026 | 1.09 Mn |
| Dec 31, 2025 | 487,000.00 |
| Sep 30, 2025 | 376,000.00 |
| Jun 30, 2025 | 400,000.00 |
| Mar 31, 2025 | 608,000.00 |
| Dec 31, 2024 | 598,000.00 |
| Sep 30, 2024 | 666,000.00 |
| Jun 30, 2024 | 449,000.00 |
| Mar 31, 2024 | 384,000.00 |
| Dec 31, 2023 | 612,000.00 |
| Sep 30, 2023 | 423,000.00 |
| Jun 30, 2023 | 414,000.00 |
| Mar 31, 2023 | 166,000.00 |
| Dec 31, 2022 | 2,427.00 |
| Sep 30, 2022 | 7,236.00 |
| Jun 30, 2022 | 2,269.00 |
| Mar 31, 2022 | 33,068.00 |
| Dec 31, 2021 | 2,759.00 |
| Sep 30, 2021 | 4,256.00 |